Time New York: Thu 19 Oct 23:24 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Endo (ENDP) Q2 Earnings Beat Estimates, 2017 Guidance Cut

Zacks

Dublin, Ireland-based Endo International plc ENDP is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.

Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.

Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 14.44%.

Endo International PLC Price and EPS Surprise


Endo International PLC Price and EPS Surprise | Endo International PLC Quote

Currently, Endo has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Endo beat second-quarter 2017 earnings. The company reported EPS of 93 cents while our consensus called for EPS of 74 cents.

Revenues: Revenues also surpassed expectations. Endo posted revenues of $875.7 million which beat Zacks Consensus Estimate of $847 million.

Key Stats: Revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.

2017 Guidance Lowered: Endo lowered its revenue guidance in the range of $3.38 billion to $3.53 billion for 2017 compared to $3.45 billion to $3.60 billion expected previously. The company expects earnings from continuing operations in the range of $3.35 to $3.65 per share as against $3.45 to $3.75 expected previously. The Zacks Consensus Estimate for earnings is $3.47 per share on revenues of $3.48 billion.

Pre-Market Trading: Shares were down more than 3% in the pre-market trading.

Check back later for our full write up on this ENDP earnings report later!

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.